Lung Cancer

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

An ambitious clinical trial set to start in July will match patients to treatments based on molecular abnormalities, rather than cancer types, testing 20 targeted drugs at once.

E-cigarettes, championed by some as a smoking-cessation tool, may actually decrease the likelihood of quitting smoking, according to a recent population-based study of 1,000 smokers published in The American Journal of Public Health.

It's incredible how much personality was squeezed into my mother's 4'10" frame. She was a spitfire. A burst of energy, starting friendly conversations with anyone and everyone she met.

After nearly four years of cancer treatment, I thought I'd experienced all possible types of scanxiety. I was wrong.

Finding specialized care is worth the effort for patients with uncommon cancers.

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.

Preliminary data from a phase 2 trial demonstrates that a combination of the PARP inhibitor veliparib and chemotherapy benefits patients with squamous cell non-small cell lung cancer.

Readers respond to past CURE articles on living with mesothelioma, hospice, beating bladder cancer, lung cancer, and response to CURE's 2007 Cancer Resource Guide.

Asbestos exposure is the main cause of mesothelioma, accounting for more than 80 percent of cases.